Waters Corporation (0LTI.L)
USD 337.48
(-3.05%)
USD 337.48
(-3.05%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.76 Billion USD | 0.28% |
| 2022 | 1.72 Billion USD | 5.8% |
| 2021 | 1.62 Billion USD | 19.92% |
| 2020 | 1.35 Billion USD | -2.67% |
| 2019 | 1.39 Billion USD | -2.2% |
| 2018 | 1.42 Billion USD | 4.8% |
| 2017 | 1.36 Billion USD | 6.74% |
| 2016 | 1.27 Billion USD | 6.36% |
| 2015 | 1.19 Billion USD | 3.03% |
| 2014 | 1.16 Billion USD | 3.9% |
| 2013 | 1.12 Billion USD | 1.33% |
| 2012 | 1.1 Billion USD | -1.31% |
| 2011 | 1.12 Billion USD | 13.19% |
| 2010 | 990.06 Million USD | 9.54% |
| 2009 | 903.81 Million USD | -1.1% |
| 2008 | 913.85 Million USD | 8.54% |
| 2007 | 841.92 Million USD | 13.16% |
| 2006 | 744.04 Million USD | 9.44% |
| 2005 | 679.88 Million USD | 4.64% |
| 2004 | 649.72 Million USD | 15.95% |
| 2003 | 560.35 Million USD | 8.49% |
| 2002 | 516.49 Million USD | -5.74% |
| 2001 | 547.97 Million USD | 3.55% |
| 2000 | 529.16 Million USD | 12.88% |
| 1999 | 468.8 Million USD | 15.64% |
| 1998 | 405.4 Million USD | 32.14% |
| 1997 | 306.8 Million USD | 19.15% |
| 1996 | 257.5 Million USD | 15.32% |
| 1995 | 223.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 363.01 Million USD | -25.76% |
| 2024 Q3 | 463.34 Million USD | 4.77% |
| 2024 Q2 | 407.63 Million USD | 12.29% |
| 2023 Q2 | 439.5 Million USD | 9.79% |
| 2023 Q1 | 400.29 Million USD | -21.56% |
| 2023 Q4 | 488.96 Million USD | 16.34% |
| 2023 FY | 1.72 Billion USD | 0.28% |
| 2023 Q3 | 420.28 Million USD | -4.37% |
| 2022 Q3 | 401.45 Million USD | -1.39% |
| 2022 Q4 | 510.32 Million USD | 27.12% |
| 2022 FY | 1.72 Billion USD | 5.8% |
| 2022 Q1 | 404.88 Million USD | -16.59% |
| 2022 Q2 | 407.11 Million USD | 0.55% |
| 2021 Q4 | 485.44 Million USD | 25.08% |
| 2021 FY | 1.62 Billion USD | 19.92% |
| 2021 Q2 | 401.39 Million USD | 13.26% |
| 2021 Q3 | 388.1 Million USD | -3.31% |
| 2021 Q1 | 354.39 Million USD | -23.96% |
| 2020 Q3 | 331.44 Million USD | 8.01% |
| 2020 Q2 | 306.85 Million USD | 20.67% |
| 2020 FY | 1.35 Billion USD | -2.67% |
| 2020 Q1 | 254.29 Million USD | -39.05% |
| 2020 Q4 | 466.08 Million USD | 40.62% |
| 2019 Q3 | 336.22 Million USD | -3.83% |
| 2019 FY | 1.39 Billion USD | -2.2% |
| 2019 Q1 | 292.83 Million USD | -31.61% |
| 2019 Q2 | 349.61 Million USD | 19.39% |
| 2019 Q4 | 417.22 Million USD | 24.09% |
| 2018 Q4 | 428.15 Million USD | 27.09% |
| 2018 FY | 1.42 Billion USD | 4.8% |
| 2018 Q2 | 353.08 Million USD | 14.17% |
| 2018 Q1 | 309.24 Million USD | -25.81% |
| 2018 Q3 | 336.88 Million USD | -4.59% |
| 2017 Q3 | 329.69 Million USD | 0.33% |
| 2017 FY | 1.36 Billion USD | 6.74% |
| 2017 Q4 | 416.82 Million USD | 26.43% |
| 2017 Q1 | 286.87 Million USD | -23.95% |
| 2017 Q2 | 328.62 Million USD | 14.55% |
| 2016 Q4 | 377.2 Million USD | 22.28% |
| 2016 Q2 | 316.18 Million USD | 15.35% |
| 2016 Q1 | 274.09 Million USD | -21.39% |
| 2016 FY | 1.27 Billion USD | 6.36% |
| 2016 Q3 | 308.48 Million USD | -2.43% |
| 2015 Q1 | 271.15 Million USD | -22.69% |
| 2015 Q3 | 293.77 Million USD | 2.71% |
| 2015 Q4 | 348.69 Million USD | 18.69% |
| 2015 FY | 1.19 Billion USD | 3.03% |
| 2015 Q2 | 286.03 Million USD | 5.49% |
| 2014 Q1 | 242.78 Million USD | -27.84% |
| 2014 Q2 | 279.94 Million USD | 15.31% |
| 2014 Q3 | 290.94 Million USD | 3.93% |
| 2014 Q4 | 350.75 Million USD | 20.56% |
| 2014 FY | 1.16 Billion USD | 3.9% |
| 2013 FY | 1.12 Billion USD | 1.33% |
| 2013 Q4 | 336.45 Million USD | 26.61% |
| 2013 Q1 | 255.77 Million USD | -18.39% |
| 2013 Q3 | 265.74 Million USD | 1.13% |
| 2013 Q2 | 262.78 Million USD | 2.74% |
| 2012 Q1 | 253.16 Million USD | -20.18% |
| 2012 Q2 | 272.2 Million USD | 7.52% |
| 2012 Q3 | 267.25 Million USD | -1.82% |
| 2012 Q4 | 313.4 Million USD | 17.27% |
| 2012 FY | 1.1 Billion USD | -1.31% |
| 2011 Q1 | 257.77 Million USD | -12.42% |
| 2011 FY | 1.12 Billion USD | 13.19% |
| 2011 Q3 | 274.21 Million USD | 0.99% |
| 2011 Q4 | 317.17 Million USD | 15.67% |
| 2011 Q2 | 271.52 Million USD | 5.33% |
| 2010 Q2 | 235.92 Million USD | 6.38% |
| 2010 FY | 990.06 Million USD | 9.54% |
| 2010 Q4 | 294.32 Million USD | 23.64% |
| 2010 Q3 | 238.05 Million USD | 0.9% |
| 2010 Q1 | 221.76 Million USD | -14.28% |
| 2009 Q4 | 258.71 Million USD | 17.16% |
| 2009 FY | 903.81 Million USD | -1.1% |
| 2009 Q2 | 218.68 Million USD | 6.36% |
| 2009 Q3 | 220.82 Million USD | 0.98% |
| 2009 Q1 | 205.59 Million USD | -16.51% |
| 2008 FY | 913.85 Million USD | 8.54% |
| 2008 Q4 | 246.26 Million USD | 8.11% |
| 2008 Q3 | 227.79 Million USD | 1.9% |
| 2008 Q2 | 223.53 Million USD | 3.37% |
| 2008 Q1 | 216.26 Million USD | -15.2% |
| 2007 Q1 | 187.54 Million USD | -16.48% |
| 2007 Q3 | 198.95 Million USD | -0.72% |
| 2007 Q2 | 200.41 Million USD | 6.86% |
| 2007 Q4 | 255.01 Million USD | 28.17% |
| 2007 FY | 841.92 Million USD | 13.16% |
| 2006 FY | 744.04 Million USD | 9.44% |
| 2006 Q2 | 175.89 Million USD | 3.72% |
| 2006 Q1 | 169.59 Million USD | -14.47% |
| 2006 Q3 | 174.01 Million USD | -1.07% |
| 2006 Q4 | 224.54 Million USD | 29.04% |
| 2005 FY | 679.88 Million USD | 4.64% |
| 2005 Q2 | 167.56 Million USD | 7.07% |
| 2005 Q3 | 157.52 Million USD | -5.99% |
| 2005 Q4 | 198.29 Million USD | 25.88% |
| 2005 Q1 | 156.5 Million USD | -19.33% |
| 2004 FY | 649.72 Million USD | 15.95% |
| 2004 Q1 | 147.61 Million USD | -8.86% |
| 2004 Q2 | 154.3 Million USD | 4.54% |
| 2004 Q3 | 153.79 Million USD | -0.33% |
| 2004 Q4 | 194.01 Million USD | 26.15% |
| 2003 Q4 | 161.96 Million USD | 19.68% |
| 2003 FY | 560.35 Million USD | 8.49% |
| 2003 Q3 | 135.33 Million USD | -0.68% |
| 2003 Q1 | 126.78 Million USD | 20.47% |
| 2003 Q2 | 136.26 Million USD | 7.47% |
| 2002 Q4 | 105.24 Million USD | -25.43% |
| 2002 Q3 | 141.13 Million USD | -0.05% |
| 2002 Q2 | 141.21 Million USD | 9.54% |
| 2002 Q1 | 128.9 Million USD | -19.13% |
| 2002 FY | 516.49 Million USD | -5.74% |
| 2001 Q1 | 137.09 Million USD | -8.91% |
| 2001 Q2 | 131.25 Million USD | -4.25% |
| 2001 Q4 | 159.41 Million USD | 23.03% |
| 2001 Q3 | 129.57 Million USD | -1.28% |
| 2001 FY | 547.97 Million USD | 3.55% |
| 2000 Q4 | 150.5 Million USD | 16.12% |
| 2000 Q1 | 120.13 Million USD | -12.44% |
| 2000 Q2 | 128.91 Million USD | 7.31% |
| 2000 Q3 | 129.61 Million USD | 0.55% |
| 2000 FY | 529.16 Million USD | 12.88% |
| 1999 Q1 | 104.8 Million USD | -10.5% |
| 1999 FY | 468.8 Million USD | 15.64% |
| 1999 Q4 | 137.2 Million USD | 20.25% |
| 1999 Q3 | 114.1 Million USD | 1.06% |
| 1999 Q2 | 112.9 Million USD | 7.73% |
| 1998 FY | 405.4 Million USD | 32.14% |
| 1998 Q4 | 117.1 Million USD | 18.4% |
| 1998 Q3 | 98.9 Million USD | 0.51% |
| 1998 Q2 | 98.4 Million USD | 8.01% |
| 1998 Q1 | 91.1 Million USD | -6.95% |
| 1997 Q3 | 70 Million USD | -1.27% |
| 1997 Q4 | 97.9 Million USD | 39.86% |
| 1997 Q1 | 68 Million USD | -1.16% |
| 1997 FY | 306.8 Million USD | 19.15% |
| 1997 Q2 | 70.9 Million USD | 4.26% |
| 1996 FY | 257.5 Million USD | 15.32% |
| 1996 Q3 | 66.4 Million USD | 2.0% |
| 1996 Q2 | 65.1 Million USD | 13.81% |
| 1996 Q1 | 57.2 Million USD | -5.3% |
| 1996 Q4 | 68.8 Million USD | 3.61% |
| 1995 Q3 | 54.3 Million USD | -4.74% |
| 1995 Q1 | 51.5 Million USD | 0.0% |
| 1995 FY | 223.3 Million USD | 0.0% |
| 1995 Q4 | 60.4 Million USD | 11.23% |
| 1995 Q2 | 57 Million USD | 10.68% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 93.36% |
| uniQure N.V. | 2.21 Million USD | -79412.099% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2166.74% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -10069.138% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -386.477% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 562781.47% |
| bluebird bio, Inc. | -4.03 Million USD | 43802.06% |
| Blueprint Medicines Corporation | 236.58 Million USD | -644.426% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -11804.779% |
| Imunon, Inc. | -720 Thousand USD | 244708.44% |
| Adicet Bio, Inc. | -6.09 Million USD | 28981.486% |
| Dynavax Technologies Corporation | 182.11 Million USD | -867.067% |
| Editas Medicine, Inc. | -99.52 Million USD | 1869.545% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -17438.269% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 18510.966% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 66.383% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 18.804% |
| Myriad Genetics, Inc. | 476.4 Million USD | -269.688% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 4.666% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -61.135% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -236.271% |
| Verastem, Inc. | -62 Thousand USD | 2840733.871% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 79.538% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 88.431% |
| Biogen Inc. | 7.3 Billion USD | 75.881% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 603248.288% |
| Perrigo Company plc | 1.68 Billion USD | -4.808% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 9040.52% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2310.381% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -583076.49% |
| Geron Corporation | -123.5 Million USD | 1526.033% |
| Illumina, Inc. | 2.74 Billion USD | 35.817% |
| Homology Medicines, Inc. | -7.22 Million USD | 24462.886% |
| Nektar Therapeutics | 53.47 Million USD | -3193.304% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 5750.707% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 7.518% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 3985.699% |
| Evolus, Inc. | 140.52 Million USD | -1153.286% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 84.416% |
| FibroGen, Inc. | 128.9 Million USD | -1266.283% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 49.172% |
| OPKO Health, Inc. | 318.12 Million USD | -453.613% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -16.029% |
| Exelixis, Inc. | 1.75 Billion USD | -0.201% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 541.63% |
| Zoetis Inc. | 5.83 Billion USD | 69.812% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -620.221% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 581351.815% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -126.225% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -270.081% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -176.529% |
| Insmed Incorporated | 239.63 Million USD | -634.948% |
| TG Therapeutics, Inc. | 219.1 Million USD | -703.801% |
| Incyte Corporation | 3.44 Billion USD | 48.812% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -412.124% |